Chemours™

The Chemours Company

Third Quarter Earnings Presentation

November 5, 2015

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements as further described in the “Risk Factors” section of the information statement contained in the registration statement on Form 10 and other filings made by Chemours with the Securities and Exchange Commission. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS and Adjusted EBITDA, which should not be considered as replacements of GAAP. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS and Adjusted EBITDA to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items which it believes will occur infrequently in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results prior to July 1, 2015 are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company’s website at investors.chemours.com.

Chemours™

Highlights

Launched Five-Point Transformation Plan

Realized ~$60 million in cost savings

Delivered $42 million sequential improvement in Adjusted EBITDA

Declared fourth quarter dividend

Amended credit facility

Chemours™

3Q15 Overview

($ in millions unless otherwise noted)

Financial Summary

	3Q15	2Q15	Δ Seq.	3Q14	Δ Yr/Yr
Net Sales	$1,486	$1,508	($22)	$1,632	($146)
Adj. EBITDA	169	127	42	235	(66)
Adj. EBITDA Margin (%)	*11.4*	*8.4*	*3.0*	*14.4*	*(3.0)*
Net Income	(29)	(18)	(11)	107	(136)
Adj. Net Income	73	13	60	133	(60)
EPS*	($0.16)	($0.10)	($0.06)	$0.59	($0.75)
Adj. EPS*	$0.40	$0.07	$0.33	$0.74	($0.34)
Free Cash Flow	8	(145)	153	69	(61)

- Adjusted EBITDA margin of 11.4% in spite of continued TiO_2 headwinds
- Free cash flow improvement maintained cash balance >$200M after $100M dividend payment declared pre-spin

See reconciliation of Non-GAAP measures in the Appendix
*Periods prior to 3Q15 are represented by pro forma EPS

Chemours™

Titanium Technologies Business Summary

Third Quarter Highlights

- Maintained double-digit margin as cost reductions partially mitigated lower pricing
- Sequential volume up slightly
- Decelerating, but continued pricing pressures
- Currency headwinds persist, particularly in emerging economies
- 150,000 tons of TiO_2 capacity shutdown announced and completed

Outlook Commentary

- Pricing and demand environment anticipated to remain soft
- Cost reduction initiatives will partially offset market dynamics
- Uncertainties from slower growing Chinese and Latin American economies

Financial Summary *($ millions)*

	3Q15	2Q15	3Q14
Sales	$616	$642	$754
Adjusted EBITDA	$78	$91	$189
Adjusted EBITDA Margin (%)	*12.7*	*14.2*	*25.1*

Sales Drivers

	Yr/Yr % Δ
Price	(13)
Currency	(7)
Volume	2

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Fluoroproducts Business Summary

Third Quarter Highlights

- Significant sequential improvement in segment Adjusted EBITDA
- Strong market adoption of Opteon™ refrigerants
- Normalized operations translated into higher plant utilization and lower costs
- Continued phase out of older refrigerants resulted in higher prices on lower volumes

Outlook Commentary

- Continued market penetration and growth of Opteon™ product line
- Ongoing phase out of older base refrigerants creating value opportunities
- Increased demand for polymers in highly competitive environment
- Cost reduction initiatives expected to mitigate competitive market dynamics

Financial Summary *($ millions)*

	3Q15	2Q15	3Q14
Sales	$575	$588	$572
Adjusted EBITDA	$89	$54	$70
Adjusted EBITDA Margin (%)	*15.5*	*9.2*	*12.2*

Sales Drivers

	Yr/Yr % Δ
Price	4
Currency	(6)
Volume	6
Portfolio	(3)

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Chemical Solutions Business Summary

Third Quarter Highlights

- Strong volume gains in both Sulfur and Cyanide businesses
- Lower pricing driven by lower input costs
- Asset impairment charges taken related to strategic evaluation

Outlook Commentary

- Strategic evaluation underway, excluding Cyanide business
  - Review will include options to fix, close or sell assets
  - Potential to raise proceeds and streamline capital expenditures from portfolio actions

Financial Summary *($ millions)*

	3Q15	2Q15	3Q14
Sales	$295	$278	$306
Adjusted EBITDA	$7	$4	$9
Adjusted EBITDA Margin (%)	*2.4*	*1.4*	*2.9*

Sales Drivers

	Yr/Yr % Δ
Price	(4)
Currency	(4)
Volume	4

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Adjusted EBITDA Bridge: 2Q15 – 3Q15



Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Adjusted EBITDA Bridge: 3Q14 – 3Q15

($ in millions)



Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Liquidity Position



- Quarter-end cash balance of $215M after $100M dividend payment
- Credit amendment provides improved flexibility to drive Transformation Plan
- Total Liquidity of $968M, reflects revolver availability of $753M[1]
- Anticipate pick-up in working capital unwind through year end against flat quarterly capital expenditures
- Recorded payable to DuPont under Separation Agreement, expect to pay ~$49M by yearend

[1] Based on Credit Agreement defined LTM Adjusted EBITDA including pro forma adjustments, Net Debt/EBITDA of 4.8x

Transformation Plan Priorities

Reduce Costs	• $2.4B starting cost position* includes SG&A, R&D and plant fixed costs • $200M cost reductions in 2016 • Target a total of $350M of structural reductions in 2017
Optimize The Portfolio	• Evaluate strategic alternatives for Chemical Solutions portfolio, excluding Cyanides
Grow Market Positions	• Support customer growth in TiO_2 through successful Altamira start-up • Continue ramp up of Opteon™ product line in Fluoroproducts • Grow Cyanides business within Chemical Solutions
Refocus Investments	• Concentrate capital spending on investable business portfolio • Invest in the next increment of Opteon™ and Cyanides capacity • Rationalize annual capital spending to ~$350M in 2017
Enhance Our Organization	• Foster an entrepreneurial organization • Operate with a simpler structure • Maintain a commitment to a safe and sustainable future

Enhance Adjusted EBITDA by $500M and Improve Leverage Position to ~3x in 2017

*Trailing twelve months ended 6/30/15

Progress On Transformation Plan

($ in millions)

Cost Reduction Initiatives Underway

Near-Term Outlook Commentary

+ Continued cost reductions from transformation plan
+ Growth from Opteon™
+ Seasonal working capital reduction in fourth quarter
– Continued soft TiO_2 market dynamics
– Weak global economic conditions
– Seasonally lower volumes in fourth quarter

Actions taken in the past four months expected to deliver annualized benefits in excess of $200M

Chemours™

Appendix

Adjusted EBITDA to GAAP Net (Loss) Income Reconciliation

($ in millions unless otherwise noted)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Total Adjusted EBITDA	$169	$235	$441	$671
Interest	(51)	-	(79)	-
Depreciation and amortization	(70)	(57)	(201)	(185)
Non-operating pension and other postretirement employee benefit costs	10	(3)	(5)	(18)
Exchange gains (losses)	44	(33)	47	(29)
Asset impairments	(70)	-	(70)	-
Restructuring charges	(139)	-	(200)	(21)
Gains (losses) on sale of business or assets	-	1	-	12
(Loss) income before income taxes	(107)	143	(67)	430
(Benefit from) provision for income taxes	(78)	35	(63)	108
Net (loss) income	($29)	$108	($4)	$322
Less: Net income attributable to noncontrolling interests	-	1	-	1
Net (loss) income attributable to Chemours	($29)	$107	($4)	$321
Basic (loss) earnings per share of common stock	($0.16)	$0.59	($0.02)	$1.77
Diluted (loss) earnings per share of common stock	($0.16)	$0.59	($0.02)	$1.77

GAAP Net (Loss) Income to Adjusted Net Income Reconciliation

($ in millions unless otherwise noted)

	Three Months Ended September 30,		Nine Months Ended September 30,		Three Months Ended June 30,
	2015	2014	2015	2014	2015
Net (loss) income attributable to Chemours	($29)	$107	($4)	$321	($18)
Restructuring charges	139	–	200	21	61
Asset impairments	70	–	70	–	-
Exchange (gains) losses	(44)	33	(47)	29	(19)
Non-operating pension and other postretirement employee benefit costs	(10)	3	5	18	8
(Gains) losses on sale of business or assets	–	(1)	–	(12)	-
(Benefit from) provision for income taxes	(53)	(9)	(74)	(14)	(19)
Adjusted Net Income	$73	$133	$150	$363	$13
Adjusted Earnings Per Share, Basic	$0.40	$0.74	$0.83	$2.01	$0.07
Adjusted Earnings Per Share, Diluted	$0.40	$0.74	$0.82	$2.01	$0.07

Chemours™

Chemours™